This article is more than 5 years old. Information may no longer be current.

VIDEO: Choy discusses efficacy of tocilizumab as monotherapy, combined with csDMARDs for RA treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

LONDON — At the EULAR Annual Congress, Ernest Choy, MB BCh, MD, FRCP, discussed the use of subcutaneous tocilizumab as a monotherapy or combined with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) to treat patients with rheumatoid arthritis (RA). He said subcutaneous tocilizumab offers similar efficacy as intravenous tocilizumab and may be another treatment option.